Peritoneal Carcinomatosis from Gastric Cancer: A Multi-Institutional Study of 159 Patients Treated by Cytoreductive Surgery Combined with Perioperative Intraperitoneal Chemotherapy

Gléhen, Olivier; Gilly, François Noël; Arvieux, C.; Cotte, Eddy; Boutitie, Florent; Mansvelt, B.; Bereder, Jean Marc; Lorimier, G.; Quénet, François; Élias, Dominique

doi:10.1245/s10434-010-1039-7

Cited by 421 publications

(357 citation statements)

References 33 publications

Supporting

Mentioning

329

Contrasting

Unclassified

Order By: Relevance

“…Extended PC necessarily requires more extensive surgery, longer OT time, greater blood loss and consequently is associated with higher complication rates. In certain disease types like peritoneal metastases of colorectal and gastric origin, a high PCI (PCI > 17 for colorectal and PCI > 12 for gastric) is associated with a poorer overall survival as well [43,44]. In these settings, intraoperative assessment of the PCI and experience of surgeon probably represent the better way to select patients for CRS and HIPEC and limiting post-operative mortality and morbidity.…”

Section: Risk Factors For Complicationsmentioning

confidence: 99%

Complications of Cytoreductive Surgery and HIPEC in the Treatment of Peritoneal Metastases

Mehta

Gelli

Agarwal

et al. 2016

Indian J Surg Oncol

View full text Add to dashboard Cite

The combined treatment concept of cytoreductive surgery (CRS) and Hyperthermic intraperitoneal chemotherapy (HIPEC) has shown to be an efficient therapeutic option for selected patients with primary and secondary peritoneal carcinomatosis (PC). This strategy represents the standard of care for diseases like pseudomyxoma peritonei and peritoneal mesothelioma, and offers the best long-term results for PC from colorectal cancer. Despite these results, skepticism exists regarding this therapeutic approach partly because of its perceived high toxicity. In this article, we review the current evidence on complications that can occur after CRS and HIPEC and the risk factors associated with increased incidence of morbidity and mortality.

show abstract

Section: Risk Factors For Complicationsmentioning

confidence: 99%

Complications of Cytoreductive Surgery and HIPEC in the Treatment of Peritoneal Metastases

Mehta

Gelli

Agarwal

et al. 2016

Indian J Surg Oncol

View full text Add to dashboard Cite

show abstract

“…[33,34] It is also shown benefit for gastric cancer with limited peritoneal spread and has been the only modality that has the potential to prolong survival in this sub group of patients with a very poor prognosis otherwise. [35,36].…”

Section: Rationale For Hyperthermic Intraperitoneal Chemotherapy (Hipec)mentioning

confidence: 99%

The role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: A Review

Bhatt

Gléhen

2016

Indian J Surg Oncol

Self Cite

View full text Add to dashboard Cite

Ovarian cancer is one of the leading causes of cancer related deaths in women worldwide. It is usually diagnosed in an advanced stage (Stages III and IV) when peritoneal cancer spread has already occurred. The standard treatment comprises of surgery to remove all macroscopic disease followed by systemic chemotherapy. Despite all efforts, it recurs in over 75 % of the cases, most of these recurrences being confined to the peritoneal cavity. Recurrent ovarian cancer has a poor long term outcome and is generally treated with multiple lines of systemic chemotherapy and targeted therapy. The propensity of ovarian cancer to remain confined to the peritoneal cavity warrants an aggressive locoregional approach. The combined treatment comprising of cytoreductive surgery (CRS) that removes all macroscopic disease and HIPEC (Hyperthermic Intraperitoneal Chemotherapy) has been effective in providing long term survival in selected patients with peritoneal metastases of gastrointestinal origin. Intraperitoneal chemotherapy used as adjuvant therapy has shown a survival benefit in ovarian cancer. This has prompted the use of CRS and HIPEC in the management of ovarian cancer as a part of first line therapy and second line therapy for recurrent disease. This article reviews the current literature and evidence for the use of HIPEC in ovarian cancer.

show abstract

“…PC has been estimated to be responsible for 60% of all gastric cancer-associated mortalities, with peritoneal metastases in these patients considered terminal (6,20,21). Therapy consists mainly of palliative chemotherapy; long-term survival is considered poor, since systemic chemotherapy agents are unlikely to reach cytotoxic concentrations in peritoneal nodules (22)(23)(24)(25)(26)(27).…”

Section: Discussionmentioning

confidence: 99%

Hyperthermic intraperitoneal perfusion chemotherapy and response evaluation in patients with gastric cancer and malignant ascites

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

Abstract. The present study describes the use of bidirectional chemotherapy in the treatment of patients with gastric cancer and peritoneal carcinomatosis (PC), using newly developed response criteria for the treatment of malignant ascites. In addition, the association between effusion response and survival was analyzed. Between June 2010 and May 2014, patients affected by malignant ascites secondary to unresectable PC of gastric origin were treated with a combination of systemic and loco-regional chemotherapy. Cisplatin (75 mg/m 2 ) at an inflow temperature of 43˚C was infused intraperitoneally, and docetaxel (75 mg/m 2 ) was infused simultaneously via a peripheral vein, on day 1 every 3 weeks. The primary endpoint was overall survival rate, and the secondary endpoint was efficacy against malignant ascites using new response criteria. In total, 41 patients were enrolled, the majority of whom received 6 cycles of intraperitoneal chemotherapy in combination with hyperthermia. The majority of patients exhibited clinical regression of ascites and relief of associated symptoms. Malignant ascites disappeared [complete response (CR)] or decreased by 50% [partial response (PR)] in 73.2% of patients. No mortalities associated with the procedures occurred. The median survival time was 8.6 months, and the 1-year survival rate was 24.4%. As these new response criteria for the treatment of malignant ascites were found to be feasible, bidirectional chemotherapy may be the preferred strategy for the treatment of gastric cancer with PC. The CR, PR and non-PR groups showed significant differences in overall survival, indicating that decreased effusion was associated with improved patient survival.

show abstract

Peritoneal Carcinomatosis from Gastric Cancer: A Multi-Institutional Study of 159 Patients Treated by Cytoreductive Surgery Combined with Perioperative Intraperitoneal Chemotherapy

Cited by 421 publications

References 33 publications

Complications of Cytoreductive Surgery and HIPEC in the Treatment of Peritoneal Metastases

Complications of Cytoreductive Surgery and HIPEC in the Treatment of Peritoneal Metastases

The role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer: A Review

Hyperthermic intraperitoneal perfusion chemotherapy and response evaluation in patients with gastric cancer and malignant ascites

Contact Info

Product

Resources

About